• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Pharmacokinetics,distribution,and excretion of sodium oligomannate,a recently approved anti-Alzheimer's disease drug in China

    2022-04-07 12:46:50JiaojiaoLuQiongqunPanJieqiangZhouYanWengKailiChenLvShiGuanxiuZhuChunlinChenLiangLiMeiyuGengZhenqingZhang
    Journal of Pharmaceutical Analysis 2022年1期

    Jiaojiao Lu,Qiongqun Pan,Jieqiang Zhou,Yan Weng,Kaili Chen,Lv Shi,Guanxiu Zhu,Chunlin Chen,Liang Li,*,Meiyu Geng,Zhenqing Zhang

    aJiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases;College of Pharmaceutical Sciences,Soochow University,Suzhou,Jiangsu,215021,China

    bShanghai Green Valley Pharma.Corp.,Shanghai,201203,China

    cMedicilon Preclinical Research(Shanghai)LLC,Shanghai,201299,China

    dState Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China

    Keywords:

    Sodium oligomannate

    Alzheimer's disease

    Pharmacokinetics

    LC-MS/MS

    Oligosaccharide

    A B S T R A C T

    The National Medical Products Administration has authorized sodium oligomannate for treating mild-tomoderate Alzheimer's disease.In this study,an LC-MS/MS method was developed and validated to quantitate sodium oligomannate in different biomatrices.The plasma pharmacokinetics,tissue distribution,and excretion of sodium oligomannate in Sprague-Dawley rats and beagle dogs were systematically investigated.Despite its complicated structural composition,the absorption,distribution,metabolism,and excretion profiles of the oligosaccharides in sodium oligomannate of different sizes and terminal derivatives were indiscriminate.Sodium oligomannate mainly crossed the gastrointestinal epithelium through paracellular transport following oral administration,with very low oral bioavailability in rats(0.6%-1.6%)and dogs(4.5%-9.3%).Absorbed sodium oligomannate mainly resided in circulating body fluids in free form with minimal distribution into erythrocytes and major tissues.Sodium oligomannate could penetrate the blood-cerebrospinal fluid(CSF)barrier of rats,showing a constant area under the concentration-time curve ratio(CSF/plasma)of approximately 5%.The cumulative urinary excretion of sodium oligomannate was commensurate with its oral bioavailability,supporting that excretion was predominantly renal,whereas no obvious biliary secretion was observed following a single oral dose to bile duct-cannulated rats.Moreover,only 33.7%(male)and 26.3%(female)of the oral dose were recovered in the rat excreta within 96 h following a single oral administration,suggesting that the intestinal flora may have ingested a portion of unabsorbed sodium oligomannate as a nutrient.

    1.Introduction

    Sodium oligomannate was found to be safe and effective for treating mild-to-moderate Alzheimer's disease(AD)in clinical phase II and phase III studies[1,2].It was authorized by the National Medical Products Administration(NMPA)of China in November 2019 and became available to the Chinese market in December 2019[3,4].It is the only drug approved worldwide in almost 17 years to treat mild-to-moderate AD[5].This approval is great news to patients,family members,and doctors.

    Sodium oligomannate is derived from alginate via two chemical modification steps[6].Alginate is a linear polysaccharide extracted from brown seaweeds and is composed of β-D-mannuronic acid(M)and α-L-guluronic acid(G)with an exclusive 1→4 linkage[7,8].Homogenous polymannuronic acid(M block),polyguluronic acid(G block)domains,and heterogeneous polymanuronic/polyguluronic acid domain(M/G block)occur in alginate[9,10].Partial hydrolysis breaks the M/G block and releases M and G blocks.Subsequently,sodium oligomannate was produced from the purified M block with oxidative degradation.Sodium oligomannate is characterized as β-1-4-linked oligomannuronic acid with certain molecular weight distribution(degree of polymerization from 2 to 10)and a series of mannuronic acid-derived polyhydroxy dicarboxylic acid residues at the reducing terminal of each sugar chain(Fig.1).

    Fig.1.Representative chemical structure of sodium oligomannate(dp:degree of polymerization;n=2 to 10).

    Recently,sodium oligomannate was reported to treat mild-tomoderate AD by indirectly regulating gut microbiota,that is,the gut-brain axis mechanism[11].Sodium oligomannate can directly inhibit amyloid-β fibril formation[12,13].As a drug with a novel mechanism for treating neurodegenerative diseases,with potentially new neuro-clinical indications[11]but a complicated structural composition,it is important to verify whether sodium oligomannate enters the systemic circulation and then the brain after oral administration.However,it is crucial to clarify the mechanism of sodium oligomannate.Few methods have been developed and validated for analyzing sodium oligomannate directly in a biological matrix with high accuracy,sensitivity,specificity,and efficiency,as it has an intrinsically complex structure,such as a relatively high molecular weight(670-880 Da),high polarity(carbohydrate-based structure),and complicated composition(size normally distributed and sugar chain terminal derivatives randomly distributed).Thus,the absorption,distribution,metabolism,and excretion(ADME)study of sodium oligomannate lags behind other pharmaceutical studies and clinical studies.

    Several methods have been considered to determine sodium oligomannate concentrations in biometrics.However,most of these methods have proven inadequate.The specificity of antibody assays is affected by endogenous glycans,such as heparin,hyaluronic acid,heparan sulfate,dermatan sulfate,and N/O-glycans[14-16].Biofunctional assays are limited by the problems of amyloid-β-related stability and operability[17,18].Moreover,none of the bioassays can effectively discriminate sugar chains of different sizes in biological samples[19-21].Due to its low sample volume requirements,high selectivity,and high sensitivity,LC-MS/MS has become the preferred method for ADME studies[22-24].A few LCMS/MS methods have been reported for the quantitation of oligosaccharides in biological samples,but chemical or enzymatic degradation and post-degradation derivatization before analysis are generally required[25,26].

    Here,we developed an LC-MS/MS method to quantify sodium oligomannate directly in different animal biomatrices,including rat plasma,urine,cerebrospinal fluid(CSF),feces,bile,tissues,and dog plasma.Based on this method,we are trying to answer several important questions:1)whether,how,and how much sodium oligomannate enters the systemic circulation and CSF following oral administration;2)whether the ADME behaviors of oligosaccharides with different sizes of sodium oligomannate are the same;and 3)whether sodium oligomannate is metabolized in vivo?The results will help us understand the anti-Alzheimer mechanism of sodium oligomannate and deepen our understanding of its efficacy and safety in clinical use.

    2.Materials and methods

    2.1.Chemicals and reagents

    Sodium oligomannate was provided by Shanghai Green Valley Pharmaceutical Co.,Ltd.(Shanghai,China).The internal standard(IS)d8-valine was purchased from Sigma-Aldrich(St.Louis,MO,USA).All reagents and solvents were of HPLC or analytical grade and were obtained from reliable commercial sources.

    2.2.Animals

    Sprague-Dawley(SD)rats(SPF grade,180-240 g,6-8 weeks)were purchased from Sino-British SIPPR/BK Lab Animal Ltd.(Shanghai,China)and kept under a 12 h light/dark cycle in a temperature-controlled(25°C)room.SPF rodent growth and reproduction feed and reverse osmosis(RO)purified water were provided ad libitum.All beagle dogs(5.7-10.6 kg)were purchased from Beijing Marshall Biotechnology Co.,Ltd.(Beijing,China).The dog maintenance feed and RO purified water were provided ad libitum.

    2.3.Oligosaccharide profile of sodium oligomannate

    2.3.1.Preparation of standard samples using blank matrices for oligosaccharide profiling

    Stock solutions of sodium oligomannate were prepared in ultrapure water.A series of standard working solutions were prepared by diluting the stock solution with water.The standard working solution(2 μL)was added to 38 μL of the blank matrix(plasma,urine,CSF,or fecal homogenate),and the mixture was vortexed for 1 min to generate the standard samples.It is well known that the concentration of an analyte affects greatly the accuracy of mass spectral detection,and a wide range of sodium oligomannate concentrations in biological matrices after oral or intravenous administration can also be expected.Under these circumstances,the concentration range of the prepared standard samples was roughly equivalent to the expected actual concentration range of sodium oligomannate in the corresponding biological matrices.

    2.3.2.Drug administration for oligosaccharide profiling

    An appropriate amount of sodium oligomannurate was weighed,added to the required amount of sterile water for injection,vortexed,and sonicated to obtain a colorless or light-yellow transparent solution.Following a single oral administration of sodium oligomannate at different dosages to SD rats or beagle dogs,blood,urine,and feces samples were collected individually predose and at given time points.Immediately after the collection of blood samples into EDTA-K2tubes,plasma was collected by centrifugation.All samples were stored at-70°C prior to the analysis.Details of the drug dosage,collected substrates,and sampling time points are presented in Table 1.

    Table 1Animals,dosage,matrix,and sampling time points after oral administration.

    2.3.3.Sample preparation

    Protein precipitation methods were used to extract sodium oligomannates from biological samples.For each plasma or CSF sample(50 μL),250 μL of extraction solvent(ethanol:acetonitrile:water=34:51:15,containing 50μg/mL d8-valine as an IS)was added.The mixture was vortexed for 2 min and then centrifuged at 18,000 r/min for 7 min.The supernatant was then ready for LC-MS/MS analysis.For rat urine and bile samples,equal volumes of rat plasma were added,and the mixed samples were processed using the same procedure as that used for the plasma sample.Feces and tissue samples were homogenized with ultrapure water at a volume:weight ratio of 10 mL/g.A total of 100μL blank plasma(500 μL)and extraction solvent were added to 100 μL of homogenate,vortexed for 2 min,and then centrifuged at 18,000 r/min for 7 min.The supernatant was analyzed using LC-MS/MS.

    2.3.4.LC-MS/MS conditions

    The accurate mass and characteristic fragment ions of each component in sodium oligomannate were confirmed using an HILIC-UPLC-Orbitrap MS/MS system(data not shown).Based on these results,the characteristic ion pairs(precursor ion→product ion)of each sodium oligomannate component were selected to construct the multiple reaction monitoring(MRM)ion reaction in LC-MS/MS analysis,and the MS conditions of each ion reaction were optimized to improve the detection sensitivity.

    The analyte and IS were separated using a Waters Atlantis?T3(150 mm ×2.1 mm I.D.,3μm)column on a Waters Acquity UPLC system(Milford,MA,USA).The mobile phase was 10 mM ammonium formate in water(mobile phase A)and acetonitrile(mobile phase B),with gradients programmed as follows:initial 5%B maintained for 1.4 min,which was increased to 95%B after 0.4 min,maintained for 1.2 min,then decreased to 5%B in 0.1 min,and maintained for 1.4 min.The flow rate was 0.25 mL/min.An SCIEX Triple Quad?6500 tandem mass spectrometer(Concord,Canada)with an electrospray ionization source was used in the negative mode for mass detection.The MS parameters were as follows:ion spray voltage,-4,500 V;ion source temperature,500°C;curtain gas,35 a.u.;nebulizing gas(GS1),50 a.u.;auxiliary gas(GS2),50 a.u.;and declustering potential,80 V.The collision energy was optimized for each tested sugar chain.

    2.3.5.Sodium oligomannate oligosaccharide profiling in biosamples

    Because of the interference of endogenous substances in biological matrices,particularly due to their low content and poor ionization efficiency,components with a large degree of polymerization(dp;6 to 10)cannot be accurately determined using the above-mentioned LC-MS/MS method.However,the oligosaccharides of dp2-dp5 are major components of the drug according to their specifications(approximately 85%)based on refractive index detection.Thus,in this study,the smaller-sized components(dp2 to dp5)of sodium oligomannate were used to construct the oligosaccharide profile to understand whether oligosaccharides with different sizes behave indiscriminately.The MRM transitions of these components are listed in Table 2.

    Table 2The formula,characteristic ions,and collision energy(CE)of each oligosaccharide in sodium oligomannate.

    The peak area of each oligosaccharide detected in the MRM mode in LC-MS/MS was integrated.The relative percentage based on the peak area of each oligosaccharide component in a sample was calculated by dividing the peak area by the sum of the peak areas of all components.Consequently,an oligosaccharide profile of sodium oligomannate was constructed.

    2.4.Method validation

    Based on the results obtained from the oligosaccharide profiling studies,a representative component,dp2-2(m/z 355.0→193.0),was selected as the MS detection indicator of sodium oligomannate to develop a bioanalytical method with d8-valine as the IS(m/z 124.0→45.0).Subsequently,the established LC-MS/MS method for absolute quantification of sodium oligomannate concentrations in biological samples was fully validated in accordance with the United States Food and Drug Administration(FDA)Guidance for Industry for Bioanalytical Method Validation,which included system suitability,selectivity,linearity,carryover,accuracy and precision,dilution,recovery,matrix effect,and stability.

    2.5.Pharmacokinetic studies in rats

    Fifty SD rats were randomly assigned to five groups consisting of equal numbers of male and female rats(n=10 in each group).The animals were fasted overnight prior to drug administration and until 4 h after administration.Rats from group 1 received an intravenous bolus injection of sodium oligomannate at a 2 mg/kg dosage.Serial blood samples(pre-dose,0.083,0.25,0.5,0.75,1,1.5,2,4,8,and 24 h)were collected from the jugular vein into EDTA-K2tubes.Rats from groups 2-4 received gavage doses of 100,200,and 400 mg/kg.Serial blood samples(pre-dose,0.167,0.33,0.5,1,2,4,6,8,10,and 24 h)were collected.For rats from group 5,multiple gavage doses of sodium oligomannate at 200 mg/kg/day were administered for 8 days before serial blood samplings(pre-dose on days 4,5,6,7,and 8,and 0.167,0.33,0.5,1,2,4,6,8,10,and 24 h post-dose on day 8)were collected.Plasma was collected by centrifuging the blood at 3,000 g for 5 min and stored at-70°C until analysis.

    Pharmacokinetic parameters,including area under the plasma concentration versus time curve(AUC),plasma clearance(CLP),elimination half-life(t1/2),mean residence time(MRT),and volume of distribution(Vz),were calculated via a non-compartmental method using the Phoenix WinNonlin 7.0 software(Certara,Princeton,NJ,USA).

    2.6.Tissue distribution studies in rats

    Twenty-four SD rats were randomly assigned to three groups(n=8 per group)with equal numbers of male and female rats.The animals were fasted overnight prior to drug administration 4 h later.Following oral administration of 400 mg/kg of sodium oligomannate,blood samples were collected from the cardiac punctures at 0.25(group 1),1(group 2),and 6 h(group 3),and plasma was collected by centrifuging the blood at 3,000 g for 5 min.After blood sample collection,representative tissues or organs,including the brain,heart,lung,liver,stomach,spleen,kidney,skeletal muscle,abdominal fat,testis(ovary),uterus,bladder,small intestine,and large intestine,were dissected,washed with saline solution,weighed,dried,and stored at-70°C until analysis.

    2.7.Plasma protein binding

    The in vitro binding of sodium oligomannate to rat and beagle dog plasma proteins was determined at concentrations of 1,10,and 100 μM.Plasma samples containing sodium oligomannate(100μL)were subjected to equilibrium dialysis(n=3)against an equal volume of phosphate-buffered saline(PBS,pH 7.4)at 37°C with gentle shaking at 60 r/min.After 5 h of equilibration,samples were drawn from the buffer chambers,and the plasma chambers were added with the same volume of plasma or PBS to achieve the same conditions.The mixtures were then diluted with 85% aqueous ethanol containing 10μg/mL IS,and the supernatant was analyzed by LCMS/MS.

    The concentration of the compound was expressed as the peak area ratio(peak area sodium oligomannate/peak area internal standard),and the protein binding rate was calculated according to the following formula:

    2.8.Blood-brain barrier permeability in rats

    A total of 150 male SD rats were randomly assigned to three groups(n=50 in each group).Animals from each group were then divided into ten subgroups according to time points(n=5 for each time group).Animals were fasted overnight prior to drug administration and received an intravenous bolus injection of sodium oligomannate at doses of 20,40,and 60 mg/kg.Blood samples were collected from the jugular vein into EDTA-K2tubes at predetermined time points(pre-dose,0.083,0.25,0.5,1,2,4,8,10,and 24 h).Plasma was collected by centrifuging the blood at 3,000 g for 5 min.CSF was collected by direct needle puncture in rats while they were anesthetized.All samples were stored at-70°C until further analysis.

    2.9.Excretion studies in rats

    Sixteen SD rats were randomly assigned to two groups(n=8 in each group)with equal numbers of male and female rats.The animals were fasted overnight prior to drug administration 4 h later.Rats from group 1 were placed separately in metabolism cages and orally administered 400 mg/kg of sodium oligomannate after an overnight fast.Urine and feces were collected during periods of 0-4,4-8,8-24,24-48,48-72,and 72-96 h after administration.Rats from group 2 were anesthetized,and bile ducts were inserted before oral administration of sodium oligomannate(400 mg/kg).Bile was collected during periods of 0-4,4-8,8-24,and 24-48 h post-dose.All samples were stored at-70°C until further analysis.

    2.10.Pharmacokinetic experiments in beagle dogs

    Twenty-four beagle dogs were randomly assigned to four groups(n=6 in each group)with equal numbers of males and females and housed individually in stainless steel mobile cages.The animals were fasted overnight prior to drug administration and until 4 h later.Dogs from group 1 received an intravenous bolus injection of sodium oligomannate at a dose of 1 mg/kg.Serial blood samples(pre-dose,0.083,0.25,0.5,1,2,3,4,6,8,and 24 h)were collected from the jugular vein into EDTA-K2--containing tubes.Dogs from groups 2 and 4 received gavage doses of 50 and 200 mg/kg,respectively.Serial blood samples(pre-dose,0.25,0.5,1,2,4,6,8,10,and 24 h)were collected.For dogs in group 3,multiple gavage doses of sodium oligomannate at 100 mg/kg/day were administered for 7 days,followed by the collection of serial blood samples(pre-dose,0.25,0.5,1,2,4,6,8,10,and 24 h at both day 1 and day 7,and pre-dose at days 4,5,and 6)were collected.Plasma was collected by centrifuging the blood at 2,200 g for 10 min and stored at-70°C until analysis.

    3.Results

    3.1.The oligosaccharide profile of sodium oligomannate

    3.1.1.The rat plasma oligosaccharide profile

    The mass spectral peak area of each of the 12 sodium oligomannate components was proportional to the concentration of sodium oligomannate in standard samples prepared with blank rat plasma at concentrations ranging from 200 to 30,000 ng/mL.The linear calibration curves are shown in Fig.2A,and regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide component dp2-2 showed the highest response,followed by dp2-1 and two trisaccharide components,dp3-1 and dp3-2.

    Fig.2.Linear calibration curves for each sodium oligomannate component in(A)rat plasma,(C)urine,(E)feces,and(G)cerebrospinal fluid(CSF)and the oligosaccharide profiles of sodium oligomannate in(B)rat plasma,(D)urine,(F)feces,and(H)CSF.

    The oligosaccharide profiles of sodium oligomannate in standard rat plasma samples and rat plasma collected at different time points following oral gavage of 3,000 mg/kg sodium oligomannate were obtained,as shown in Fig.2B.Similar oligosaccharide profiles observed in both the real plasma samples and the standard sample(spike-in)demonstrated the indiscriminate absorption of sodium oligomannate components to systematic circulation in rats following oral gavage.In addition,oligosaccharide profiles of sodium oligomannate did not change significantly with pharmacokinetic sampling time,indicating that the clearance of sodium oligomannate from the systemic circulation was also indiscriminate.

    3.1.2.The rat urine oligosaccharide profile

    The mass spectral peak area of each of the 12 sodium oligomannate components was proportional to the concentration of sodium oligomannate in standard samples prepared with blank rat urine at concentrations ranging from 1,000 to 200,000 ng/mL.The linear calibration curves are shown in Fig.2C,and the regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide component dp2-2 showed the highest response,followed by dp3-1,dp2-1,and dp3-2.The oligosaccharide profiles of sodium oligomannate in standard rat urine samples and in rat urine collected at different time points following oral gavage of 1,000 mg/kg sodium oligomannate are shown in Fig.2D.Similar oligosaccharide profiles were observed in both the real urine samples and the spiked urine sample.The fact that oligosaccharide profiles did not change significantly with the sampling periods strongly suggests the indiscriminate elimination of sodium oligomannate components from rat kidneys.

    3.1.3.The rat feces oligosaccharide profile

    The mass spectral peak areas of each of the twelve sodium oligomannate components were proportional to the concentration of sodium oligomannate in the standard samples prepared with blank rat fecal homogenate at concentrations ranging from 100 to 1,800μg/mL.The linear calibration curves are shown in Fig.2E,and regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide component dp2-2 showed the highest response,followed by dp2-1,dp3-1,and dp3-2.The oligosaccharide profiles of sodium oligomannate in standard rat feces samples and rat feces collected at different periods following oral gavage of 1,000 mg/kg sodium oligomannate are shown in Fig.2F.Similar oligosaccharide profiles were observed in both real fecal samples and the spike-in feces sample.The fact that oligosaccharide profiles did not change significantly with the sampling periods strongly suggests indiscriminate elimination of sodium oligomannate components from the rat intestine.

    3.1.4.The rat CSF oligosaccharide profile

    The mass spectral peak areas of each of the seven sodium oligomannate components were proportional to the concentration of sodium oligomannate in the standard samples prepared with blank rat CSF at concentrations ranging from 50 to 5,000 ng/mL.The linear calibration curves are shown in Fig.2G,and regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide components dp2-2 and dp2-1 showed relatively high responses.The oligosaccharide profiles of sodium oligomannate in the standard rat CSF sample and rat CSF collected at different periods following intravenous injection of 40 mg/kg sodium oligomannate are shown in Fig.2H.Similar oligosaccharide profiles were observed in both the real CSF samples and the spiked CSF sample.The fact that oligosaccharide profiles did not change significantly with the sampling time strongly suggests the indiscriminate distribution of sodium oligomannate components in rat CSF.

    3.1.5.The dog plasma oligosaccharide profile

    To verify whether there was any difference between species,the oligosaccharide profile in dog plasma was also investigated.Similar to the observations in rats,similar oligosaccharide profiles observed in both the real plasma samples and the spike-in plasma sample demonstrated the indiscriminate absorption and clearance of sodium oligomannate components in dogs following oral gavage 300 mg/kg sodium oligomannate.Detailed data are shown in the supplementary data(Fig.S1).

    3.2.LC-MS/MS method validation

    The highly similar oligosaccharide profiles observed in the prepared samples and the actual biological samples after drug administration suggest that each of these components can be used as an indicator of sodium oligomannate in mass spectral detection.To obtain a higher detection sensitivity,a representative disaccharide component of sodium oligomannate,dp2-2 (m/z 355.0→193.0),was used to develop a bioanalytical method with d8-valine as the IS(m/z 124.0→45.0).Calibration curves for sodium oligomannate were fitted via linear weighted(1/x2)leastsquares regression.

    The established LC-MS/MS method for absolute quantification of sodium oligomannate concentration was fully validated in rat plasma,urine,liver homogenate,and dog plasma,and partially validated in rat blood,fecal homogenate,bile,and tissue homogenate(other than liver),according to the Guidance for Industry for Bioanalytical Method Validation issued by both the United States FDA and the NMPA of China.The results of full validation in rat plasma,urine,liver homogenate,and dog plasma,including system suitability,selectivity,linearity,carryover,accuracy and precision,dilution, recovery, matrix effect, stability and typical chromatograms,are shown in Supplementary data,Tables S2-S5,and Figs.S2-S5.The validated linear ranges of sodium oligomannate concentrations in the biological matrices are shown in Table 3.

    Table 3The calibration ranges of sodium oligomannate concentrations in biological matrices.

    3.3.Pharmacokinetic of sodium oligomannate in SD rats

    Concentrations of sodium oligomannate in rat plasma were quantified using a fully validated LC-MS/MS method.The mean plasma concentration versus time profiles for sodium oligomannate in male and female rats are shown in Figs.3A-C,and the main pharmacokinetic parameters are presented in Table 4.

    Table 4Pharmacokinetic parameters of sodium oligomannate in Sprague-Dawley rats.

    Following single intravenous administration of 2 mg/kg sodium oligomannate,AUC(0-t)for male and female rats were 2.49 and 2.04h·μg/mL,respectively.Vzvalues were relatively small(546mL/kg for males and494mL/kg for females)compared with 670mL/kg of the total body water in rats,indicating minimal extravascular distribution.Circulating sodium oligomannate underwent rapid clearance as indicated by the short terminal t1/2values(0.49h in males and 0.36h in females).In accordance,the drug exhibited high blood clearance of 2319 and 2885 mL/h/kg(obtained by dividing CLPby the blood/plasma ratio of 0.33)inmale and female rats,which are comparable to the rat renal blood flow(2200 mL/h/kg).

    Following a single oral administration of 100,200,or 400 mg/kg sodium oligomannate,the increase in mean maximum plasma concentrations(Cmax)for male(1:1.5:3.1)and female(1:1.6:2.1)rats,as well as for plasma exposure(AUC(0-t))in female rats(1:1.3:2.5)were less than dose-proportional,whereas the increase in AUC(0-t)in male rats(1:2.5:5.9)was slightly higher than doseproportional(Fig.3D).The time to maximum concentration(tmax)in male and female rats was 0.6-2.47 h and 0.4-3.77 h,respectively.MRT was 1.93-3.82 h and 2.99-4.16 h,respectively,in males and females.The oral bioavailability of sodium oligomannate in rats was determined to be 0.1%-1.6%.

    Fig.3.The mean plasma concentration-time profiles of sodium oligomannate in rats(A)after a single 2.0 mg/kg intravenous administration;(B)after single or multiple oral doses in males;(C)after single or multiple oral doses in females;(D)exposure-dose relationship after single oral doses of 100,200,and 400 mg/kg.

    After repeated oral doses of sodium oligomannate(200 mg/kg)to SD rats for 8 days,there was no significant difference in the plasma concentration values before the fourth,fifth,sixth,seventh,and eighth dosing(roughly around the LLOQ,0.100μg/mL),indicating that the plasma exposure to sodium oligomannate reached a steady state.After multiple doses,the tmaxand MRT values did not change significantly compared with those from a single dose.The Cmaxratios(RCmax)of the last dose to the first dose for male and female rats were 4.1 and 1.6,and the AUC0-tratios(RAUC)were 2.2(males)and 1.6(females),respectively,indicating that there was a certain accumulation in SD rats following a repeated oral dose.

    3.4.Tissue distribution of sodium oligomannate in SD rats

    Sodium oligomannate concentrations in male and female rat tissue samples collected at 0.25,1,and 6 h after oral administration of 400 mg/kg are presented in Fig.4.It was mainly distributed in the gastrointestinal tract,while the concentrations in other organs and tissues were low.At 0.25 h after administration,higher drug concentrations were observed in the small intestine and stomach,whereas the small intestine and large intestine were the principal organs of sodium oligomannate distribution at 1 h and 6 h postdose,respectively.

    Fig.4.The concentration of sodium oligomannate in(A)male and(B)female rat tissues at 0.25,1,and 6 h after a single 400 mg/kg oral dose.

    3.5.Plasma protein binding of sodium oligomannate

    The in vitro binding of sodium oligomannate to rat and beagle dog plasma proteins was determined by equilibrium dialysis.The results showed that the binding rate of the drug to rat and dog plasma proteins was less than 7.4% and virtually 0,respectively,in the concentration range of 1-100μM.

    3.6.Blood-brain barrier permeability of sodium oligomannate in SD rats

    To investigate whether sodium oligomannate could penetrate the blood-brain barrier to reach the brain,male SD rats were administered three doses by intravenous injection.Serial blood and CSF samples were collected,and LC-MS/MS quantified the concentrations of sodium oligomannate.The mean plasma and CSF concentration versus time profiles for sodium oligomannate are shown in Figs.5A and B,respectively.Exposure of rat plasma and CSF to sodium oligomannate was dose-proportional(Fig.5C).

    Fig.5.Mean plasma concentration-time profiles of sodium oligomannate in(A)rat plasma and(B)CSF after single intravenous administration.(C)The exposure-dose relationship after single intravenous doses of 20,40,and 60 mg/kg.

    Following a single intravenous injection of 20 and 40 mg/kg to SD rats,sodium oligomannate was detected in the CSF as early as 5 min after the dose.The mean peak CSF concentrations were 454.4 and 1215.4 ng/mL,with a tmaxof 0.5 h.Following a single 60 mg/kg intravenous injection of sodium oligomannate,peak CSF concentration(1406.4 ng/mL)was observed at the first sampling time point(5 min).Plasma/CSF exposure(AUCPlasma/AUCCSF)of sodium oligomannate at 20,40,and 60 mg doses were 31,912/1420,63,744/3209,85,757/4334 h·ng/mL,respectively.The mean bioavailability(obtained by dividing AUCCSFby AUCPlasma)of sodium oligomannate to rat CSF was 4.45%,5.03%,and 5.05%,respectively.

    3.7.Excretion of sodium oligomannate in SD rats

    Both intact and bile duct-cannulated(BDC)rats were used to determine the excretion routes of sodium oligomannate following an oral dose of 400 mg/kg.Concentrations of sodium oligomannate in rat urine,feces,and bile were measured by LC-MS/MS analysis.The cumulative excretion amounts in rat urine,feces,and bile were calculated,and the cumulative excretion percentage curves are shown in Fig.6.At 96 h post-dosing,35.2%(1.2% in urine,0.3% in wash solution,and 33.7% in feces)and 27.1%(0.8% in urine,0.1% in wash solution,and 26.3% in feces)of sodium oligomannate were excreted into male and female rat urine and feces,respectively.Bile excretion in male and female bile duct-cannulated rats accounted for less than 0.004% of the dose within 48 h after administration.

    Fig.6.Cumulative excretion curves of sodium oligomannate after a single 400 mg/kg oral dose to SD rats,(A)in 0-96 h urine;(B)in 0-96 h feces;(C)total recovery in urine and feces after 0-96 h.

    3.8.Pharmacokinetics of sodium oligomannate in beagle dogs

    Concentrations of sodium oligomannate in dog plasma were quantified using a fully validated LC-MS/MS method.The mean plasma concentration versus time profiles for sodium oligomannate in male and female dogs are shown in Figs.7A-C,and the main pharmacokinetic parameters are presented in Table S6.Following single intravenous administration of 1 mg/kg sodium oligomannate,the AUC(0-t)for male and female dogs was 2.95 and 3.31 h·μg/mL,respectively.The Vzvalues(380 mL/kg for males and 360 mL/kg for females)were roughly comparable to the extracellular fluid in dogs(280 mL/kg)and much less than the total body water in dogs(600 mL/kg),indicating minimal extravascular distribution in dogs.Rapid clearance of sodium oligomannate from circulation was revealed by the short terminal t1/2in male(0.81 h)and female dogs(0.86 h).The CLp of sodium oligomannate in male and female dogs were determined to be 321 and 290 mL/h/kg,respectively,and due to the lack of the blood/plasma ratio,its blood clearance in dogs was not determined.

    After a single oral administration of 50,100,and 200 mg/kg sodium oligomannate,the increases in Cmaxand AUC(0-t)for male(1:1.1:1.8 for Cmaxand 1:1.1:1.9 for AUC)and female(1:1.2:1.7 for Cmaxand 1:1.3:2.4 for AUC)dogs were less than dose-proportional(Fig.7D).The tmaxand MRT values in male and female dogs were 0.7-1.7 h and 3.4-6.2 h,respectively.The oral bioavailability of sodium oligomannate in dogs was determined to be 4.2%-9.3%.

    Fig.7.Mean plasma concentration-time profiles of sodium oligomannate in dogs(A)after a single 1.0 mg/kg intravenous administration;(B)after single or multiple oral doses in males;(C)after single or multiple oral doses in females;(D)exposure-dose relationship after single oral doses of 50,100 and 200 mg/kg.

    Following repeated oral doses of sodium oligomannate(100 mg/kg)for 7 days,there was no significant difference in the plasma concentration values before the fourth,fifth,sixth,and seventh dosing in male dogs(roughly around the LLOQ,0.100μg/mL),whereas the trough concentration increased slightly in female dogs over time(0.15,0.25,0.23,and 0.31μg/mL before the fourth,fifth,sixth,and seventh dosing).Compared to the first dose,tmaxand MRT after multiple doses did not change significantly.RCmaxof the last dose to the first dose for male and female dogs was 0.8 and 1.2,and the RAUCvalues for male and female dogs were 1.0 and 1.2,respectively,indicating no accumulation in dogs following a repeated oral sodium oligomannate dose.

    4.Discussion

    Sodium oligomannate,a newly authorized drug for the improvement of cognitive function in patients with mild-to-moderate AD,was found to reduce gut microbiota dysbiosis-promoted neuroinflammation and amyloid β plaque deposition in AD progression[11-13].Due to the oligosaccharide nature of sodium oligomannate,it has long been debated whether this substance can be absorbed effectively and cross the blood-brain barrier into the central nervous system(CNS)after oral administration.It seems that it is not an ideal lead compound for CNS drugs from the perspective of traditional pharmaceutical chemists[27],such as complicated composition,relatively large molecular weight,high polarity,too many hydrogen bond donors and receptors,and strong dissociation tendency under physiological conditions(acidic pKa 3.59).

    Elucidating the ADME properties of a drug in the body is an important prerequisite for understanding drug efficacy and safety[28].However,the lack of a reliable biological method impeded the ADME evaluation of sodium oligomannate due to its complicated composition and disadvantageous physicochemical properties in view of instrument detection.

    As sodium oligomannate comprises a series of oligosaccharides with different sizes and terminal derivatives,they were profiled in various biosamples to verify if they behave differently in ADME.The comprehensive results showed no significant difference in the oligosaccharide profiles between the spiked samples and corresponding real rat plasma,urine,feces,CSF,and dog plasma samples collected over the pharmacokinetic sampling time post-dose.This finding suggests the indiscriminate absorption,distribution,and excretion of the oligosaccharides from sodium oligomannates with different sizes and terminal derivatives and no apparent intertransformation between these components.

    An LC-MS/MS method to quantify sodium oligomannate in various bio-matrixes was developed,validated,and applied based on oligosaccharide profiling.The ADME properties of sodium oligomannate in animals were investigated.

    The oral bioavailability of sodium oligomannate in rats(0.1%-1.6%)and dogs(4.2%-9.3%)was very low.In addition,sodium oligomannate showed extremely low membrane permeability(Papp<1×10-7cm/s in the concentration range of 75-300μM)in the Caco-2 cell monolayer model(data not shown).It did not act as a substrate for uptake transporters,including the organic anion transporting polypeptide 1B1(OATP1B1),OATP1B3,organic anion transporter 1(OAT1),OAT3,and organic cation transporter 2,and efflux transporters,including P-glycoprotein and breast cancer resistant protein(data not shown).Since sodium oligomannate is primarily ionized at physiological pH(7.4)due to its low acidic pKa value,it may cross the epithelium through paracellular transport[29,30].It is further postulated that rats are a better model than dogs(which tend to produce overestimations)for predicting human oral bioavailability of paracellularly absorbed compounds due to species-dependent physiological differences[31,32].Thus,the oral bioavailability of sodium oligomannate in humans is expected to be low.

    After absorption into the systemic circulation,sodium oligomannate is likely to remain in circulating body fluids with minimal extravascular distribution to most organs and tissues regardless of blood flow or blood volume,as indicated by its small Vzvalues in both rats and dogs.Circulating sodium oligomannate does not bind to albumin and mainly exists in the free form.Its distribution into erythrocytes was minimal,as indicated by its low blood/plasma ratio(0.33)in SD rats.High concentrations of sodium oligomannate were only found in the digestive tract-related organs in a timedependent gastrointestinal transport manner after a single oral dose of 400 mg in SD rats.Sodium oligomannate can quickly penetrate the blood-CSF barrier following intravenous injection,as indicated by the short tmaxvalues observed in the CSF sample(less than 0.5 h).In addition,the dose-dependent increase in sodium oligomannate exposure in both CSF(AUCCSF)and plasma(AUCPlasma)resulted in a constant AUC ratio of approximately 5%,indicating that the distribution of sodium oligomannate from the circulation to the CSF solely depends on the concentration gradient between them.In contrast,the Cmaxvalue in rat CSF increased slightly higher than the dose increases between the dose range of 20 mg/kg and 40 mg/kg,while there was no significant change at a higher dose,such as 60 mg/kg.Collectively,these data suggest a paracellular transport mechanism of sodium oligomannate that penetrates the blood-CSF barrier in SD rats[33,34].

    After a single oral administration to BDC rats,virtually no detectable sodium oligomannate was observed in the bile samples up to 48 h post-dose,indicating a minor role of biliary excretion during elimination.The cumulative urinary excretion(1.5% for males and 0.9% for females)of sodium oligomannate is equivalent to its oral bioavailability(1.3% for men and 1.0% for women),supporting a predominantly renal sodium oligomannate excretion.Considering that the oligosaccharide profiles remained the same and no significant difference was observed between bioavailability and urine excretion ratio,no metabolism was suggested.Moreover,the rapid clearance of sodium oligomannate by the rat(blood clearance comparable to the renal blood flow)and dog(CLPequal to 22%-25% of the renal blood flow)kidney resulted in a short terminal t1/2in rats(less than 0.5 h)and dogs(0.8 h)following intravenous administration.

    Interestingly,only 33.7% and 26.3% of the oral dose was recovered in male and female rats within 96 h following a single oral dose,respectively.Two factors may have contributed to this phenomenon.First,the unabsorbed sodium oligomannate in the feces sample was not fully extracted by our procedure,and second,a portion of unabsorbed sodium oligomannate was ingested by the intestinal flora as a nutrient,or both.

    In conclusion,the ADME profiles of a newly approved innovative anti-AD drug,sodium oligomannate,were investigated.The results showed that it could be absorbed into the systemic circulation after oral administration with low bioavailability.Sodium oligomannate was also detected in the CSF of rats but at a very low level.The absorbed portion was neither metabolized by the body nor distributed extensively to the tissues but was quickly excreted into the urine.The intestinal flora may ingest part of the unabsorbed drug as a nutrient,and the remaining portion is excreted with feces.

    CRediT author statement

    Jiaojiao Lu:Methodology,Investigation,Writing-Original draft preparation;Qiongqun Pan:Methodology,Investigation,Writing-Original draft preparation;Jieqiang Zhou:Methodology;Yan Weng:Data curation,Validation;Kaili Chen:Data curation,Validation;Lv Shi:Methodology;Guanxiu Zhu:Project administration, Data curation, Validation; Chunlin Chen: Project administration;Liang Li:Methodology,Investigation,Writing-Original draft preparation;Meiyu Geng:Conceptualization,Supervision,Writing-Reviewing and Editing;Zhenqing Zhang:Conceptualization,Supervision,Writing-Reviewing and Editing,Funding acquisition.

    Declaration of competing interest

    The authors declare that there are no conflicts of interest.

    Acknowledgments

    This work was supported by the National Natural Science Foundation of China(Grant No.:81673388),the Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases(Grant No.:BM2013003),and the Priority Academic Program Development of Jiangsu Higher Education Institutes(PAPD).

    Appendix A.Supplementary data

    Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpha.2021.06.001.

    国产精品亚洲av一区麻豆 | 国产欧美亚洲国产| 99久久精品国产国产毛片| 久久99精品国语久久久| 久久久久国产网址| 男女午夜视频在线观看| 91在线精品国自产拍蜜月| 交换朋友夫妻互换小说| 免费看不卡的av| av.在线天堂| 精品国产一区二区三区久久久樱花| 国产av码专区亚洲av| 亚洲av日韩在线播放| 欧美xxⅹ黑人| 最近最新中文字幕大全免费视频 | 精品福利永久在线观看| 精品久久蜜臀av无| 色婷婷久久久亚洲欧美| 欧美 日韩 精品 国产| 久久久久久久大尺度免费视频| 国产日韩欧美亚洲二区| 秋霞伦理黄片| 亚洲激情五月婷婷啪啪| 多毛熟女@视频| 亚洲精品国产色婷婷电影| 午夜福利影视在线免费观看| 91成人精品电影| 国产一区二区三区综合在线观看| 中文欧美无线码| 亚洲欧洲日产国产| 国产精品99久久99久久久不卡 | 亚洲欧美精品自产自拍| 色哟哟·www| 老司机影院成人| 国产精品久久久av美女十八| 国产免费福利视频在线观看| 国产亚洲午夜精品一区二区久久| 国产乱来视频区| 久久这里有精品视频免费| 久久99一区二区三区| 国产精品人妻久久久影院| 国产在视频线精品| 久久国产精品男人的天堂亚洲| 国产有黄有色有爽视频| 免费久久久久久久精品成人欧美视频| 欧美成人午夜精品| 久久这里有精品视频免费| 最近最新中文字幕大全免费视频 | 国产一区二区在线观看av| 在线观看免费高清a一片| 亚洲av综合色区一区| 人人妻人人爽人人添夜夜欢视频| 街头女战士在线观看网站| 黑人猛操日本美女一级片| 欧美日韩精品网址| 欧美黄色片欧美黄色片| 久久精品国产自在天天线| 亚洲,一卡二卡三卡| 飞空精品影院首页| 国产男女超爽视频在线观看| 啦啦啦在线观看免费高清www| 我要看黄色一级片免费的| 91成人精品电影| 人体艺术视频欧美日本| 亚洲av.av天堂| 99九九在线精品视频| 亚洲少妇的诱惑av| 国产成人精品无人区| 中文精品一卡2卡3卡4更新| 免费日韩欧美在线观看| 国产精品国产av在线观看| 日韩av不卡免费在线播放| 日韩在线高清观看一区二区三区| 亚洲精品日韩在线中文字幕| 在线观看美女被高潮喷水网站| 亚洲精品在线美女| 国产在线免费精品| 精品久久蜜臀av无| 国产日韩欧美视频二区| 精品亚洲成a人片在线观看| 极品少妇高潮喷水抽搐| √禁漫天堂资源中文www| 一级片'在线观看视频| 国产激情久久老熟女| 有码 亚洲区| 国产精品亚洲av一区麻豆 | 乱人伦中国视频| 久久精品国产a三级三级三级| 99久久人妻综合| 新久久久久国产一级毛片| 亚洲,欧美精品.| 香蕉国产在线看| 欧美国产精品一级二级三级| 丰满少妇做爰视频| 国产精品免费视频内射| 狂野欧美激情性bbbbbb| 欧美另类一区| 99热网站在线观看| 视频区图区小说| 最新中文字幕久久久久| 欧美日韩视频高清一区二区三区二| 最近手机中文字幕大全| 精品国产超薄肉色丝袜足j| 国语对白做爰xxxⅹ性视频网站| 日韩精品有码人妻一区| 国产成人精品久久久久久| 天天躁夜夜躁狠狠久久av| 免费高清在线观看视频在线观看| 最近最新中文字幕大全免费视频 | 国产精品av久久久久免费| 久久女婷五月综合色啪小说| 天天躁夜夜躁狠狠久久av| 国产麻豆69| 欧美精品av麻豆av| 国语对白做爰xxxⅹ性视频网站| 黄网站色视频无遮挡免费观看| 国产野战对白在线观看| 日韩在线高清观看一区二区三区| 久久国产精品大桥未久av| 亚洲av国产av综合av卡| 久久久久久伊人网av| 熟女少妇亚洲综合色aaa.| 一级毛片电影观看| 久久精品国产自在天天线| 这个男人来自地球电影免费观看 | 青春草视频在线免费观看| 国产免费又黄又爽又色| 亚洲国产毛片av蜜桃av| 中文字幕人妻丝袜制服| av一本久久久久| a级毛片黄视频| 成年av动漫网址| 99久久人妻综合| 青春草视频在线免费观看| 国产日韩欧美亚洲二区| 欧美精品亚洲一区二区| 成人二区视频| h视频一区二区三区| 日韩电影二区| 美女脱内裤让男人舔精品视频| 女人精品久久久久毛片| 久久人人爽人人片av| 亚洲,欧美,日韩| 一区二区三区精品91| 黑人猛操日本美女一级片| 亚洲欧美一区二区三区久久| 亚洲精品第二区| 多毛熟女@视频| 久久久久精品久久久久真实原创| av在线观看视频网站免费| 免费在线观看黄色视频的| 亚洲av男天堂| 久久久精品94久久精品| 国语对白做爰xxxⅹ性视频网站| 亚洲成人一二三区av| 少妇被粗大的猛进出69影院| 香蕉丝袜av| 99热国产这里只有精品6| 爱豆传媒免费全集在线观看| 国产国语露脸激情在线看| 又大又黄又爽视频免费| 十分钟在线观看高清视频www| 成人18禁高潮啪啪吃奶动态图| 少妇猛男粗大的猛烈进出视频| 性色av一级| 黄色一级大片看看| 免费久久久久久久精品成人欧美视频| 999久久久国产精品视频| 日本免费在线观看一区| 激情五月婷婷亚洲| 高清在线视频一区二区三区| 亚洲人成电影观看| 中文字幕av电影在线播放| 国产亚洲精品第一综合不卡| 汤姆久久久久久久影院中文字幕| av电影中文网址| 秋霞伦理黄片| 久久这里只有精品19| av不卡在线播放| 亚洲欧美成人精品一区二区| 七月丁香在线播放| 亚洲三区欧美一区| 天美传媒精品一区二区| 久久久a久久爽久久v久久| a级毛片在线看网站| 亚洲精品久久午夜乱码| 亚洲欧美色中文字幕在线| 2022亚洲国产成人精品| 亚洲精品国产av成人精品| 另类亚洲欧美激情| 亚洲av成人精品一二三区| 在线 av 中文字幕| 国产精品国产av在线观看| 亚洲精品日韩在线中文字幕| 日韩三级伦理在线观看| 国产一区亚洲一区在线观看| 久久这里只有精品19| 亚洲欧美成人综合另类久久久| 亚洲色图 男人天堂 中文字幕| 亚洲国产精品一区三区| 日韩 亚洲 欧美在线| 性少妇av在线| 五月伊人婷婷丁香| 制服人妻中文乱码| 亚洲精品成人av观看孕妇| 日韩一区二区视频免费看| 交换朋友夫妻互换小说| 看非洲黑人一级黄片| 午夜福利在线免费观看网站| 国产 一区精品| 久久影院123| 老司机影院成人| 久久久久久久大尺度免费视频| 秋霞伦理黄片| av卡一久久| 啦啦啦视频在线资源免费观看| 午夜激情av网站| av女优亚洲男人天堂| 国产成人欧美| av视频免费观看在线观看| 成人亚洲欧美一区二区av| 亚洲av成人精品一二三区| 在线观看免费高清a一片| 亚洲精品在线美女| 免费看不卡的av| 国产成人精品久久久久久| 国产成人精品福利久久| 如日韩欧美国产精品一区二区三区| 伦理电影免费视频| 久久久久久免费高清国产稀缺| 亚洲欧美成人精品一区二区| 在线观看免费日韩欧美大片| 狂野欧美激情性bbbbbb| 九草在线视频观看| 色婷婷av一区二区三区视频| 久久国内精品自在自线图片| 狠狠精品人妻久久久久久综合| 精品视频人人做人人爽| 午夜福利乱码中文字幕| 国产精品二区激情视频| 国产一区有黄有色的免费视频| 欧美+日韩+精品| 国产黄色免费在线视频| 欧美精品国产亚洲| 成人漫画全彩无遮挡| 韩国高清视频一区二区三区| 伦精品一区二区三区| 国产 一区精品| 午夜福利视频精品| 中文字幕亚洲精品专区| 欧美人与善性xxx| 91午夜精品亚洲一区二区三区| 汤姆久久久久久久影院中文字幕| 可以免费在线观看a视频的电影网站 | 色视频在线一区二区三区| 黄色毛片三级朝国网站| 999精品在线视频| 不卡视频在线观看欧美| 日韩中字成人| 亚洲成人手机| 美女午夜性视频免费| 中文字幕人妻熟女乱码| 国产精品一二三区在线看| 天堂中文最新版在线下载| 高清不卡的av网站| 男女无遮挡免费网站观看| freevideosex欧美| 啦啦啦中文免费视频观看日本| 亚洲欧美精品综合一区二区三区 | 一级a爱视频在线免费观看| 国产一级毛片在线| 在线天堂中文资源库| 观看av在线不卡| 亚洲情色 制服丝袜| 亚洲精品在线美女| 18禁国产床啪视频网站| 高清黄色对白视频在线免费看| 如日韩欧美国产精品一区二区三区| 成人手机av| 2021少妇久久久久久久久久久| 国产精品蜜桃在线观看| 亚洲国产毛片av蜜桃av| 精品酒店卫生间| 亚洲成人av在线免费| 亚洲欧美一区二区三区黑人 | 国产极品粉嫩免费观看在线| 啦啦啦在线观看免费高清www| 激情五月婷婷亚洲| 2021少妇久久久久久久久久久| 韩国精品一区二区三区| 看免费成人av毛片| 成人手机av| 中国国产av一级| 在线免费观看不下载黄p国产| 精品人妻熟女毛片av久久网站| 色婷婷av一区二区三区视频| 国产片内射在线| 建设人人有责人人尽责人人享有的| 亚洲欧美日韩另类电影网站| av线在线观看网站| 久久婷婷青草| 欧美日韩综合久久久久久| 黄片无遮挡物在线观看| 两个人看的免费小视频| 9热在线视频观看99| 精品亚洲成国产av| 人人妻人人爽人人添夜夜欢视频| 精品国产乱码久久久久久小说| av电影中文网址| 18禁国产床啪视频网站| 精品午夜福利在线看| 免费黄网站久久成人精品| 人成视频在线观看免费观看| 亚洲国产欧美网| www.av在线官网国产| 亚洲国产av新网站| 男女国产视频网站| 寂寞人妻少妇视频99o| 伊人亚洲综合成人网| 亚洲美女黄色视频免费看| 99热国产这里只有精品6| 少妇人妻久久综合中文| 黄片播放在线免费| 亚洲欧美日韩另类电影网站| 欧美精品高潮呻吟av久久| 国产白丝娇喘喷水9色精品| 中文字幕人妻丝袜制服| 一区二区av电影网| 日本-黄色视频高清免费观看| 国产熟女欧美一区二区| 只有这里有精品99| 亚洲欧洲日产国产| 精品国产国语对白av| 天天影视国产精品| 午夜福利在线观看免费完整高清在| 成年女人毛片免费观看观看9 | 两性夫妻黄色片| 免费观看性生交大片5| 9热在线视频观看99| 免费观看a级毛片全部| 国产精品人妻久久久影院| 亚洲色图综合在线观看| 十八禁高潮呻吟视频| 亚洲成人av在线免费| 欧美精品国产亚洲| 久久久久国产精品人妻一区二区| 99国产综合亚洲精品| 国产精品女同一区二区软件| 久久久精品免费免费高清| 精品一区二区免费观看| 高清在线视频一区二区三区| 中文字幕人妻熟女乱码| 日本黄色日本黄色录像| 色视频在线一区二区三区| 黄片小视频在线播放| 国产男女内射视频| 国产日韩欧美在线精品| 一边亲一边摸免费视频| 80岁老熟妇乱子伦牲交| 最近最新中文字幕免费大全7| 国产精品蜜桃在线观看| 美女主播在线视频| 日韩中文字幕欧美一区二区 | 久久久久久人人人人人| 亚洲色图 男人天堂 中文字幕| 亚洲精品日本国产第一区| 亚洲国产精品一区二区三区在线| 国产精品久久久久久av不卡| 波野结衣二区三区在线| 制服人妻中文乱码| 老汉色av国产亚洲站长工具| 黑人猛操日本美女一级片| 考比视频在线观看| 亚洲综合色网址| 欧美日韩亚洲高清精品| 久久精品国产自在天天线| 精品少妇一区二区三区视频日本电影 | 亚洲国产成人一精品久久久| 亚洲精品,欧美精品| 超碰成人久久| 边亲边吃奶的免费视频| 咕卡用的链子| 日本黄色日本黄色录像| 免费观看无遮挡的男女| 欧美人与善性xxx| www.精华液| 成人午夜精彩视频在线观看| 亚洲av福利一区| 丰满饥渴人妻一区二区三| 2022亚洲国产成人精品| 777久久人妻少妇嫩草av网站| 国产成人精品福利久久| 午夜福利视频精品| 日韩,欧美,国产一区二区三区| 一本—道久久a久久精品蜜桃钙片| 欧美精品高潮呻吟av久久| 日韩精品有码人妻一区| 亚洲av综合色区一区| 日本色播在线视频| 人妻系列 视频| 伦理电影大哥的女人| 亚洲 欧美一区二区三区| 国产av一区二区精品久久| 有码 亚洲区| 亚洲第一av免费看| 女人精品久久久久毛片| 在线观看免费视频网站a站| 中国三级夫妇交换| 亚洲伊人色综图| 亚洲一级一片aⅴ在线观看| 成年av动漫网址| 大香蕉久久成人网| 精品少妇一区二区三区视频日本电影 | 国产精品国产三级国产专区5o| 只有这里有精品99| 免费黄色在线免费观看| 亚洲av电影在线进入| 夜夜骑夜夜射夜夜干| 亚洲中文av在线| 国产综合精华液| 免费大片黄手机在线观看| 亚洲国产精品一区三区| 欧美日本中文国产一区发布| 国产亚洲最大av| 午夜福利视频在线观看免费| 欧美日韩精品成人综合77777| 男人舔女人的私密视频| 日本午夜av视频| 少妇 在线观看| 久久99一区二区三区| 一级毛片我不卡| 成人毛片60女人毛片免费| 丰满少妇做爰视频| 色网站视频免费| 五月天丁香电影| 亚洲第一区二区三区不卡| 久久韩国三级中文字幕| av.在线天堂| 亚洲欧美一区二区三区久久| 午夜福利网站1000一区二区三区| 卡戴珊不雅视频在线播放| 国产一区二区激情短视频 | av免费在线看不卡| 欧美国产精品va在线观看不卡| 亚洲人成网站在线观看播放| 欧美日韩精品成人综合77777| 精品久久久精品久久久| 久久这里有精品视频免费| 国产精品成人在线| 久久久久网色| 午夜福利乱码中文字幕| 日韩精品有码人妻一区| 亚洲欧美精品综合一区二区三区 | 亚洲欧美一区二区三区黑人 | 久久精品国产亚洲av天美| 日韩中字成人| 中文乱码字字幕精品一区二区三区| 最近最新中文字幕大全免费视频 | 三上悠亚av全集在线观看| 免费观看在线日韩| 亚洲,一卡二卡三卡| 91精品三级在线观看| 亚洲伊人久久精品综合| 久久人人爽人人片av| 国产男女超爽视频在线观看| 日韩制服骚丝袜av| 亚洲国产精品一区三区| 最近手机中文字幕大全| 国产淫语在线视频| 精品国产乱码久久久久久小说| 一级a爱视频在线免费观看| 成人免费观看视频高清| 国产日韩一区二区三区精品不卡| 天天影视国产精品| 久久99蜜桃精品久久| 一本大道久久a久久精品| 亚洲国产日韩一区二区| 亚洲av福利一区| 久久久久久免费高清国产稀缺| 午夜福利在线观看免费完整高清在| 热re99久久国产66热| 捣出白浆h1v1| 亚洲成国产人片在线观看| 亚洲精品在线美女| 高清黄色对白视频在线免费看| 亚洲欧洲精品一区二区精品久久久 | 国产成人精品一,二区| 欧美日韩精品成人综合77777| 狂野欧美激情性bbbbbb| 日韩一本色道免费dvd| 丝袜美足系列| 午夜福利,免费看| 久久久久久伊人网av| 国产野战对白在线观看| 少妇被粗大猛烈的视频| 国产精品国产三级国产专区5o| 久久鲁丝午夜福利片| 大片电影免费在线观看免费| 久热久热在线精品观看| 国产精品av久久久久免费| 精品一区在线观看国产| 欧美 日韩 精品 国产| 欧美最新免费一区二区三区| 亚洲av.av天堂| 欧美国产精品va在线观看不卡| 在线天堂中文资源库| 日本猛色少妇xxxxx猛交久久| 免费看av在线观看网站| 亚洲精品日韩在线中文字幕| 亚洲国产欧美网| 男女无遮挡免费网站观看| 亚洲美女视频黄频| 麻豆乱淫一区二区| 大话2 男鬼变身卡| 亚洲 欧美一区二区三区| 日韩一区二区视频免费看| 可以免费在线观看a视频的电影网站 | xxxhd国产人妻xxx| 十八禁网站网址无遮挡| 中国国产av一级| 亚洲男人天堂网一区| 国产成人a∨麻豆精品| 老司机影院毛片| 午夜91福利影院| 1024视频免费在线观看| 天堂俺去俺来也www色官网| 少妇人妻 视频| 国产日韩欧美亚洲二区| 爱豆传媒免费全集在线观看| 深夜精品福利| 久久韩国三级中文字幕| 久久av网站| 日韩欧美精品免费久久| 大陆偷拍与自拍| 色播在线永久视频| 欧美精品人与动牲交sv欧美| 少妇 在线观看| 日韩一卡2卡3卡4卡2021年| 精品人妻一区二区三区麻豆| 久久热在线av| 亚洲国产日韩一区二区| 国产成人a∨麻豆精品| 男女啪啪激烈高潮av片| 啦啦啦啦在线视频资源| 日韩中文字幕视频在线看片| 秋霞伦理黄片| 精品卡一卡二卡四卡免费| 肉色欧美久久久久久久蜜桃| 五月天丁香电影| 欧美bdsm另类| 十八禁高潮呻吟视频| 亚洲av电影在线观看一区二区三区| 日本黄色日本黄色录像| 国产成人a∨麻豆精品| 1024视频免费在线观看| 欧美人与性动交α欧美软件| 久久久国产精品麻豆| 90打野战视频偷拍视频| 99热网站在线观看| 999精品在线视频| 亚洲av中文av极速乱| 99久久综合免费| h视频一区二区三区| 国产一区二区在线观看av| 韩国高清视频一区二区三区| 精品国产露脸久久av麻豆| 多毛熟女@视频| 国产一区有黄有色的免费视频| 亚洲欧美成人综合另类久久久| 久久精品久久久久久久性| 亚洲国产精品一区二区三区在线| 国产精品嫩草影院av在线观看| 久久久久久久久久人人人人人人| 高清不卡的av网站| 黄色一级大片看看| 侵犯人妻中文字幕一二三四区| 在线观看免费日韩欧美大片| 国产日韩欧美视频二区| 成人国产av品久久久| 我要看黄色一级片免费的| 国产福利在线免费观看视频| www.自偷自拍.com| 一本—道久久a久久精品蜜桃钙片| 国产亚洲精品第一综合不卡| 久久人人爽av亚洲精品天堂| 成人亚洲精品一区在线观看| 黄片播放在线免费| 久久久久久久久久久免费av| 日韩中文字幕欧美一区二区 | 国产成人精品一,二区| 国产一区二区 视频在线| 日韩熟女老妇一区二区性免费视频| 女性被躁到高潮视频| 精品国产乱码久久久久久小说| 在线观看人妻少妇| 一区二区三区四区激情视频| 黑丝袜美女国产一区| 一级黄片播放器| 精品国产一区二区久久| 欧美av亚洲av综合av国产av | 久久精品久久久久久久性| 日韩不卡一区二区三区视频在线| 自线自在国产av| 久久久久人妻精品一区果冻| 久久精品人人爽人人爽视色| 在线观看www视频免费| 日韩不卡一区二区三区视频在线| 尾随美女入室| 亚洲国产欧美网| 高清黄色对白视频在线免费看| 欧美亚洲日本最大视频资源| 一区在线观看完整版| av视频免费观看在线观看| 中文字幕av电影在线播放| 制服丝袜香蕉在线|